Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $4.1 million.

  • SOPHiA GENETICS's Share-based Compensation rose 1475.23% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 1148.45%. This contributed to the annual value of $16.5 million for FY2024, which is 813.93% up from last year.
  • According to the latest figures from Q3 2025, SOPHiA GENETICS's Share-based Compensation is $4.1 million, which was up 1475.23% from $4.4 million recorded in Q2 2025.
  • SOPHiA GENETICS's Share-based Compensation's 5-year high stood at $5.1 million during Q4 2024, with a 5-year trough of $639000.0 in Q1 2021.
  • Over the past 5 years, SOPHiA GENETICS's median Share-based Compensation value was $3.7 million (recorded in 2024), while the average stood at $3.5 million.
  • As far as peak fluctuations go, SOPHiA GENETICS's Share-based Compensation skyrocketed by 89726.03% in 2021, and later plummeted by 2999.14% in 2023.
  • SOPHiA GENETICS's Share-based Compensation (Quarter) stood at $3.6 million in 2021, then dropped by 28.68% to $2.6 million in 2022, then skyrocketed by 62.21% to $4.2 million in 2023, then increased by 20.59% to $5.1 million in 2024, then decreased by 18.35% to $4.1 million in 2025.
  • Its Share-based Compensation was $4.1 million in Q3 2025, compared to $4.4 million in Q2 2025 and $3.8 million in Q1 2025.